

**S5 Table. Summary of Adverse Event Occurrence Rates by Trial Phase.**

| MedDRA Preferred Term              | Reported Severity (DAIDS Grade) | Ring Intervention Phase N=158 | Observation Phase N=161 |
|------------------------------------|---------------------------------|-------------------------------|-------------------------|
| Participant with Any Adverse Event |                                 | 100 (63.3%)                   | 107 (66.5%)             |
| ABDOMINAL MASS                     | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| ABDOMINAL PAIN                     | Grade 1,2,3                     | 1 (0.6%)                      | 3 (1.9%)                |
| ABDOMINAL PAIN LOWER               | Grade 1,2                       | 5 (3.2%)                      | 3 (1.9%)                |
| ABDOMINAL PAIN UPPER               | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| ABDOMINAL TENDERNESS               | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| ABSCESS LIMB                       | Grade 2                         | 2 (1.3%)                      | 0 (0.0%)                |
| ADNEXA UTERI PAIN                  | Grade 1                         | 1 (0.6%)                      | 1 (0.6%)                |
| ANXIETY                            | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| APPENDICITIS                       | Grade 3                         | 1 (0.6%)                      | 0 (0.0%)                |
| ARTHRALGIA                         | Grade 2                         | 0 (0.0%)                      | 1 (0.6%)                |
| ASCARIASIS                         | Grade 2                         | 0 (0.0%)                      | 1 (0.6%)                |
| ASTHMA                             | Grade 1                         | 1 (0.6%)                      | 1 (0.6%)                |
| BACK PAIN                          | Grade 1                         | 2 (1.3%)                      | 1 (0.6%)                |
| BREAST PAIN                        | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| BRONCHIAL HYPERREACTIVITY          | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| BRONCHITIS                         | Grade 2                         | 5 (3.2%)                      | 4 (2.5%)                |
| CERVICAL DISCHARGE                 | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| CERVICITIS                         | Grade 1,2                       | 0 (0.0%)                      | 1 (0.6%)                |
| CERVIX ERYTHEMA                    | Grade 1                         | 2 (1.3%)                      | 1 (0.6%)                |
| CERVIX HAEMORRHAGE UTERINE         | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| CHEST PAIN                         | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |

Centre 02: Moshi, Tanzania; Centre 03: Johannesburg, South Africa; Centre 04: Durban, South Africa  
 Centre 05: DTHF, Cape Town, South Africa

| MedDRA Preferred Term  | Reported Severity (DAIDS Grade) | Ring Intervention Phase N=158 | Observation Phase N=161 |
|------------------------|---------------------------------|-------------------------------|-------------------------|
| COITAL BLEEDING        | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| CONSTIPATION           | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| CONTUSION              | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| CONVERSION DISORDER    | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| COUGH                  | Grade 1,2                       | 4 (2.5%)                      | 0 (0.0%)                |
| CYSTITIS               | Grade 1,2,3                     | 2 (1.3%)                      | 2 (1.2%)                |
| DEAFNESS UNILATERAL    | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| DEPRESSION             | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| DERMATITIS ALLERGIC    | Grade 1,2                       | 1 (0.6%)                      | 1 (0.6%)                |
| DIARRHOEA              | Grade 1,2                       | 4 (2.5%)                      | 2 (1.2%)                |
| DIZZINESS              | Grade 1                         | 3 (1.9%)                      | 1 (0.6%)                |
| DYSENTERY              | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| DYSMENORRHOEA          | Grade 1,2                       | 5 (3.2%)                      | 5 (3.1%)                |
| DYSPAREUNIA            | Grade 1                         | 1 (0.6%)                      | 1 (0.6%)                |
| DYSURIA                | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| EAR PAIN               | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| EAR PRURITUS           | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| ECZEMA                 | Grade 1,2                       | 1 (0.6%)                      | 1 (0.6%)                |
| EPISTAXIS              | Grade 1                         | 2 (1.3%)                      | 0 (0.0%)                |
| FATIGUE                | Grade 1,2                       | 1 (0.6%)                      | 1 (0.6%)                |
| FIBROADENOMA OF BREAST | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| FOLLICULITIS           | Grade 1                         | 1 (0.6%)                      | 3 (1.9%)                |
| FOOT FRACTURE          | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |

Centre 02: Moshi, Tanzania; Centre 03: Johannesburg, South Africa; Centre 04: Durban, South Africa  
Centre 05: DTHF, Cape Town, South Africa

| MedDRA Preferred Term              | Reported Severity (DAIDS Grade) | Ring Intervention Phase N=158 | Observation Phase N=161 |
|------------------------------------|---------------------------------|-------------------------------|-------------------------|
| GASTRITIS                          | Grade 1,2                       | 1 (0.6%)                      | 1 (0.6%)                |
| GASTROENTERITIS                    | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| GASTROENTERITIS SHIGELLA           | Grade 2                         | 0 (0.0%)                      | 2 (1.2%)                |
| GENITAL BURNING SENSATION          | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| GENITAL DISCOMFORT                 | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| GENITAL EROSION                    | Grade 1                         | 2 (1.3%)                      | 1 (0.6%)                |
| GENITAL ERYTHEMA                   | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| GENITAL HERPES                     | Grade 1,2                       | 2 (1.3%)                      | 3 (1.9%)                |
| GENITAL PAIN                       | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| GINGIVAL ULCERATION                | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| GONORRHOEA                         | Grade 1,2                       | 3 (1.9%)                      | 3 (1.9%)                |
| GYNAECOLOGICAL CHLAMYDIA INFECTION | Grade 1,2                       | 6 (3.8%)                      | 9 (5.6%)                |
| HAEMORRHOIDS                       | Grade 1,2                       | 1 (0.6%)                      | 1 (0.6%)                |
| HEAD INJURY                        | Grade 2                         | 0 (0.0%)                      | 1 (0.6%)                |
| HEADACHE                           | Grade 1,2                       | 13 (8.2%)                     | 10 (6.2%)               |
| HEAT RASH                          | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| INFLUENZA LIKE ILLNESS             | Grade 1,2                       | 12 (7.6%)                     | 16 (9.9%)               |
| INJURY                             | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| JOINT SPRAIN                       | Grade 2                         | 1 (0.6%)                      | 1 (0.6%)                |
| LACERATION                         | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| LARYNGITIS                         | Grade 2                         | 4 (2.5%)                      | 3 (1.9%)                |
| LARYNGOTRACHEITIS                  | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| LOWER RESPIRATORY TRACT INFECTION  | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| LYMPHADENOPATHY                    | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |

Centre 02: Moshi, Tanzania; Centre 03: Johannesburg, South Africa; Centre 04: Durban, South Africa  
Centre 05: DTHF, Cape Town, South Africa

| MedDRA Preferred Term  | Reported Severity (DAIDS Grade) | Ring Intervention Phase N=158 | Observation Phase N=161 |
|------------------------|---------------------------------|-------------------------------|-------------------------|
| MALAISE                | Grade 1                         | 2 (1.3%)                      | 0 (0.0%)                |
| MALARIA                | Grade 2                         | 4 (2.5%)                      | 2 (1.2%)                |
| MENORRHAGIA            | Grade 1,2                       | 2 (1.3%)                      | 3 (1.9%)                |
| METRORRHAGIA           | Grade 1,2                       | 9 (5.7%)                      | 17 (10.6%)              |
| MOUTH ULCERATION       | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| MUSCLE STRAIN          | Grade 1                         | 1 (0.6%)                      | 1 (0.6%)                |
| NAIL TINEA             | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| NASOPHARYNGITIS        | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| NAUSEA                 | Grade 1                         | 0 (0.0%)                      | 2 (1.2%)                |
| NECK PAIN              | Grade 2                         | 2 (1.3%)                      | 0 (0.0%)                |
| PAIN                   | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| PALPITATIONS           | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| PEPTIC ULCER           | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| PERIORBITAL ABSCESS    | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| PHARYNGITIS            | Grade 1                         | 1 (0.6%)                      | 1 (0.6%)                |
| PHARYNGOLARYNGEAL PAIN | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| PRURITUS GENITAL       | Grade 1                         | 3 (1.9%)                      | 0 (0.0%)                |
| PYREXIA                | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| RASH                   | Grade 2                         | 0 (0.0%)                      | 1 (0.6%)                |
| RASH GENERALISED       | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| RASH PRURITIC          | Grade 2                         | 2 (1.3%)                      | 0 (0.0%)                |
| RASH PUSTULAR          | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| RASH VESICULAR         | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| SINUS HEADACHE         | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |

Centre 02: Moshi, Tanzania; Centre 03: Johannesburg, South Africa; Centre 04: Durban, South Africa  
Centre 05: DTHF, Cape Town, South Africa

| MedDRA Preferred Term             | Reported Severity (DAIDS Grade) | Ring Intervention Phase N=158 | Observation Phase N=161 |
|-----------------------------------|---------------------------------|-------------------------------|-------------------------|
| SINUSITIS                         | Grade 1,2                       | 3 (1.9%)                      | 2 (1.2%)                |
| SKIN LACERATION                   | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| SOFT TISSUE INFECTION             | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| SOFT TISSUE INJURY                | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| STRESS                            | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| SUBCUTANEOUS ABSCESS              | Grade 2                         | 1 (0.6%)                      | 1 (0.6%)                |
| TINEA INFECTION                   | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| TONSILLITIS                       | Grade 2                         | 6 (3.8%)                      | 2 (1.2%)                |
| TOOTH INJURY                      | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| TOOTHACHE                         | Grade 1,2                       | 2 (1.3%)                      | 0 (0.0%)                |
| UPPER RESPIRATORY TRACT INFECTION | Grade 1,2                       | 5 (3.2%)                      | 10 (6.2%)               |
| URINARY TRACT INFECTION           | Grade 1,2                       | 7 (4.4%)                      | 3 (1.9%)                |
| UTERINE PAIN                      | Grade 1                         | 1 (0.6%)                      | 1 (0.6%)                |
| UTERINE SPASM                     | Grade 1,2                       | 0 (0.0%)                      | 2 (1.2%)                |
| VAGINAL CANDIDIASIS               | Grade 1,2                       | 18 (11.4%)                    | 17 (10.6%)              |
| VAGINAL DISCHARGE                 | Grade 1                         | 7 (4.4%)                      | 3 (1.9%)                |
| VAGINAL ERYTHEMA                  | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| VAGINAL INFECTION                 | Grade 2                         | 0 (0.0%)                      | 0 (0.0%)                |
| VAGINAL LACERATION                | Grade 2                         | 1 (0.6%)                      | 0 (0.0%)                |
| VAGINAL ODOUR                     | Grade 1                         | 3 (1.9%)                      | 1 (0.6%)                |
| VAGINAL PAIN                      | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| VAGINITIS BACTERIAL               | Grade 1,2                       | 15 (9.5%)                     | 13 (8.1%)               |
| VIRAL RHINITIS                    | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |

Centre 02: Moshi, Tanzania; Centre 03: Johannesburg, South Africa; Centre 04: Durban, South Africa  
Centre 05: DTHF, Cape Town, South Africa

| MedDRA Preferred Term      | Reported Severity (DAIDS Grade) | Ring Intervention Phase N=158 | Observation Phase N=161 |
|----------------------------|---------------------------------|-------------------------------|-------------------------|
| VULVAL ERYTHEMA            | Grade 1                         | 1 (0.6%)                      | 0 (0.0%)                |
| VULVAR EROSION             | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| VULVOVAGINAL DISCOMFORT    | Grade 1                         | 2 (1.3%)                      | 1 (0.6%)                |
| VULVOVAGINAL DRYNESS       | Grade 1                         | 0 (0.0%)                      | 1 (0.6%)                |
| VULVOVAGINAL PRURITUS      | Grade 1                         | 2 (1.3%)                      | 2 (1.2%)                |
| VULVOVAGINITIS TRICHOMONAL | Grade 1,2                       | 1 (0.6%)                      | 3 (1.9%)                |

Centre 02: Moshi, Tanzania; Centre 03: Johannesburg, South Africa; Centre 04: Durban, South Africa  
Centre 05: DTHF, Cape Town, South Africa